There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.
Guido Dietrich
Advertisement
Director of bulk technologies at GlaxoSmithKline Biologicals
Articles by Guido Dietrich
Advertisement
Latest Updated Articles
Developing and Manufacturing Attenuated Live Bacterial VaccinesPublished: October 2nd 2008 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
3
Welcome to CPHI Frankfurt 2025
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
